Biogen Inc. (NASDAQ:BIIB) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Biogen Inc. (NASDAQ:BIIB) have earned a consensus recommendation of “Moderate Buy” from the twenty-nine brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $217.2593.

BIIB has been the subject of a number of recent research reports. Needham & Company LLC upgraded Biogen from a “hold” rating to a “buy” rating and set a $255.00 price objective for the company in a research note on Monday. HC Wainwright reiterated a “buy” rating on shares of Biogen in a research note on Thursday, May 14th. Piper Sandler restated an “overweight” rating and issued a $225.00 price target (up from $214.00) on shares of Biogen in a research note on Friday, May 15th. Canaccord Genuity Group upped their price target on Biogen from $230.00 to $245.00 and gave the stock a “buy” rating in a research note on Wednesday, April 1st. Finally, UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and upped their price target for the stock from $185.00 to $225.00 in a research note on Wednesday, April 22nd.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC boosted its stake in Biogen by 1.5% in the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after purchasing an additional 65 shares during the period. Caerus Investment Advisors LLC boosted its stake in Biogen by 5.0% in the 1st quarter. Caerus Investment Advisors LLC now owns 2,801 shares of the biotechnology company’s stock worth $514,000 after purchasing an additional 134 shares during the period. Financial Solutions Advisory Group Inc. bought a new position in Biogen in the 1st quarter worth approximately $252,000. Glenmede Trust Co. NA boosted its stake in Biogen by 17.5% in the 1st quarter. Glenmede Trust Co. NA now owns 11,652 shares of the biotechnology company’s stock worth $2,136,000 after purchasing an additional 1,733 shares during the period. Finally, Groupama Asset Managment boosted its stake in Biogen by 3.8% in the 1st quarter. Groupama Asset Managment now owns 8,753 shares of the biotechnology company’s stock worth $1,605,000 after purchasing an additional 322 shares during the period. 87.93% of the stock is currently owned by institutional investors.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: At Biogen’s 2026 annual meeting, shareholders backed the board, auditor, and pay-related proposals, signaling continued investor support for management and governance. Biogen Shareholders Back Board, Auditor and Pay Policies
• Positive Sentiment: Biogen has recently outperformed other biotech stocks, with commentary noting that analysts remain reasonably upbeat about its prospects. How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?
• Neutral Sentiment: Denali Therapeutics highlighted that it halted joint work with Biogen on BIIB122 for Parkinson’s disease after Phase 2b results, which appears to be a program setback but is not necessarily a direct blow to Biogen’s broader business. What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
• Negative Sentiment: Two shareholder-law firms, Schall and Pomerantz, announced investigations into possible false or misleading statements by Biogen, increasing the risk of litigation headlines and potential investor uncertainty. BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB
• Negative Sentiment: MarketWatch also noted that Biogen underperformed peers on Wednesday, suggesting the stock has been lagging some competitors despite its recent longer-term strength. Biogen Inc. stock underperforms Wednesday when compared to competitors

Biogen Trading Up 2.9%

Shares of NASDAQ:BIIB opened at $199.96 on Friday. The stock has a 50 day moving average of $188.40 and a 200 day moving average of $184.20. The company has a market cap of $29.52 billion, a PE ratio of 21.45 and a beta of 0.20. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. Biogen has a 12-month low of $121.05 and a 12-month high of $205.97.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm’s revenue was up 1.9% on a year-over-year basis. During the same period in the previous year, the company posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities research analysts expect that Biogen will post 14.18 EPS for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.